{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:04:11Z","timestamp":1791057851638,"version":"4.1.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031085","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T16:40:23Z","timestamp":1328114423000},"page":"e31085","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)\/CpG Immunotherapy"],"prefix":"10.1371","volume":"7","author":[{"given":"Lyse A.","family":"Norian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Kresowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Rosevear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britnie R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Rosean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara A.","family":"Kucaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Weydert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cncr.24713","article-title":"Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.","volume":"116","author":"S Patil","year":"2010","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1002\/cncr.24236","article-title":"Immunotherapy of metastatic renal cell carcinoma.","volume":"115","author":"DF McDermott","year":"2009","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1993.11.10.1969","article-title":"Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.","volume":"11","author":"JA Sparano","year":"1993","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).","volume":"22","author":"J Atzpodien","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.","volume":"13","author":"G Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-09-2273","article-title":"New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance.","volume":"16","author":"BI Rini","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.","volume":"271","author":"RM Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis.","volume":"3","author":"SR Wiley","year":"1995","journal-title":"Immunity"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2009.06.066","article-title":"TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.","volume":"625","author":"PA Holoch","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/156652309787354612","article-title":"TRAIL gene therapy: from preclinical development to clinical application.","volume":"9","author":"TS Griffith","year":"2009","journal-title":"Curr Gene Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2010.519701","article-title":"TRAIL receptor signaling and therapeutics.","volume":"14","author":"J Abdulghani","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1083\/jcb.201004096","article-title":"Clearance of apoptotic cells: implications in health and disease.","volume":"189","author":"MR Elliott","year":"2010","journal-title":"J Cell Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy.","volume":"117","author":"AM Krieg","year":"2007","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation.","volume":"374","author":"AM Krieg","year":"1995","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CJI.0b013e318174a4df","article-title":"Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.","volume":"31","author":"MA Hofmann","year":"2008","journal-title":"J Immunother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"11980","DOI":"10.1158\/0008-5472.CAN-07-1526","article-title":"Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL\/CpG oligodeoxynucleotide combination therapy.","volume":"67","author":"RL VanOosten","year":"2007","journal-title":"Cancer Res"},{"key":"ref17","first-page":"575","article-title":"Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.","volume":"30","author":"H Kobayashi","year":"2010","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-09-1758","article-title":"Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.","volume":"16","author":"L Wang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/1078-0432.CCR-09-1605","article-title":"T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.","volume":"15","author":"A Shablak","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-8-42","article-title":"Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.","volume":"8","author":"JA Westwood","year":"2010","journal-title":"J Transl Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.juro.2009.08.110","article-title":"Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model.","volume":"183","author":"SF Matin","year":"2010","journal-title":"J Urol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.urology.2006.08.1073","article-title":"RENCA\/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.","volume":"68","author":"O Shvarts","year":"2006","journal-title":"Urology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma.","volume":"4","author":"RC Flanigan","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"10445","DOI":"10.1158\/0008-5472.CAN-07-1955","article-title":"Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy.","volume":"67","author":"RU Svensson","year":"2007","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10585-006-9011-4","article-title":"Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.","volume":"22","author":"JM Drake","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-08-2826","article-title":"Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.","volume":"69","author":"LA Norian","year":"2009","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1074-7613(03)00177-8","article-title":"Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments.","volume":"19","author":"BD Elzey","year":"2003","journal-title":"Immunity"},{"key":"ref28","first-page":"3358","article-title":"Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.","volume":"46","author":"RR Salup","year":"1986","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.gt.3302999","article-title":"Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.","volume":"14","author":"JW Yockman","year":"2007","journal-title":"Gene Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/jnci\/djn113","article-title":"Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.","volume":"100","author":"A Shanker","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","article-title":"Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.","volume":"70","author":"JS Ko","year":"2010","journal-title":"Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00262-010-0865-6","article-title":"Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.","volume":"59","author":"FG Rocha","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.","volume":"181","author":"S Kusmartsev","year":"2008","journal-title":"J Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.4049\/jimmunol.168.7.3484","article-title":"Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.","volume":"168","author":"N Seki","year":"2002","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/icb.2010.40","article-title":"Langerhans cells: critical regulators of skin immunity?","volume":"88","author":"BE Clausen","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.4049\/jimmunol.179.3.1960","article-title":"Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.","volume":"179","author":"P Yu","year":"2007","journal-title":"J Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.","volume":"207","author":"SA Quezada","year":"2010","journal-title":"J Exp Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.imlet.2005.03.019","article-title":"Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice.","volume":"99","author":"S Lv","year":"2005","journal-title":"Immunol Lett"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/dna.2007.0633","article-title":"An anti-double-stranded DNA monoclonal antibody induced by tumor cell-derived DNA inhibits the growth of tumor in vitro and in vivo via triggering apoptosis.","volume":"27","author":"Q Cao","year":"2008","journal-title":"DNA Cell Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00001622-200105000-00012","article-title":"Renal cell carcinoma.","volume":"13","author":"PA Godley","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"ref41","first-page":"1","article-title":"Current management of advanced and metastatic renal cell carcinoma.","volume":"7","author":"MH Ather","year":"2010","journal-title":"Urol J"},{"key":"ref42","first-page":"6255","article-title":"Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.","volume":"61","author":"ME Gruys","year":"2001","journal-title":"Cancer Res"},{"key":"ref43","first-page":"5414","article-title":"Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.","volume":"50","author":"TJ Sayers","year":"1990","journal-title":"Cancer Res"},{"key":"ref44","first-page":"207","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.","volume":"63","author":"N Seki","year":"2003","journal-title":"Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1023\/A:1026286108366","article-title":"Induction of necrotic tumor cell death by TRAIL\/Apo-2L.","volume":"8","author":"TJ Kemp","year":"2003","journal-title":"Apoptosis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1158\/0008-5472.CAN-09-0685","article-title":"Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.","volume":"69","author":"A Shanker","year":"2009","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"721s","DOI":"10.1158\/1078-0432.CCR-06-2197","article-title":"Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.","volume":"13","author":"AC Ochoa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cncr.21951","article-title":"Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.","volume":"107","author":"WS Webster","year":"2006","journal-title":"Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semcancer.2007.06.004","article-title":"Immune suppression in renal cell carcinoma.","volume":"17","author":"B Frankenberger","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.","volume":"65","author":"AH Zea","year":"2005","journal-title":"Cancer Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.","volume":"69","author":"H Xin","year":"2009","journal-title":"Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/0008-5472.CAN-09-1574","article-title":"Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.","volume":"70","author":"MW Teng","year":"2010","journal-title":"Cancer Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/cgt.2010.2","article-title":"Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.","volume":"17","author":"PJ Wysocki","year":"2010","journal-title":"Cancer Gene Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T00:32:24Z","timestamp":1561249944000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031085"}},"subtitle":[],"editor":[{"given":"Eric J.","family":"Kremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031085","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}